In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor agonist lorcaserin.
Eisai has formally terminated a phase 3 study of lorcaserin as a potential adjunct treatment for patients with Dravet syndrome, a rare form of epilepsy that starts in infancy, according to the federal study repository clinicaltrials.gov.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,